XCures Raises $46M to Structure Fragmented Patient Records

The problem XCures is solving predates AI by decades: patient records scattered across hospitals, diagnostic labs, and telehealth platforms in formats that no system can reliably read. According to Crunchbase News, the company has closed a $46 million Series B led by Innovius Capital, at a $127 million post-money valuation, bringing total funding past $76 million since its 2018 founding.

XCures started as a spinout from Cancer Commons, initially building decision-support tools for advanced cancer patients. When the team kept hitting the same bottleneck, obtaining patient data out of fragmented healthcare systems in usable form, they pivoted to build the underlying infrastructure instead. CEO Mika Newton calls the result a "clinical clarity engine" that generates decision-ready checklists from automated patient histories. To date, the company reports processing over 300 million medical records from more than 550,000 healthcare locations nationwide.

The business metrics are the most credible part of the story. Annualized recurring revenue grew from $3 million to $10 million in 2025, with a $20 million target for 2026. The company says it hit cash-flow breakeven last year before intentionally returning to a capital-burn phase to expand the team ahead of 2027. Twenty-five enterprise clients span diagnostic firms like Exact Sciences, Caris Life Sciences, and Novocure, as well as hospital networks, telehealth providers, and Medicare Advantage plans.

Stu Posluns of Innovius framed the investment thesis around XCures' ability to "locate, extract, and normalize messy data across thousands of incompatible sources," describing the company as "building the foundational AI data layer that will power the entire healthcare industry." That is an investor's pitch, not settled fact, but the logic is coherent: before any clinical AI can work reliably, someone has to do the unglamorous work of making raw records readable.

What the reporting does not give you is detail on data privacy architecture, specifically how XCures governs the combination of proprietary ML models with commercial frontier models at this scale, or how customer revenue is distributed across those 25 clients. The tailwind is real: investors deployed roughly $8.5 billion into AI health tech at seed-to-growth stages as of June 22, 2026, per the article, meaning the market XCures serves is expanding. The infrastructure layer, though, is also the one that tends to attract both regulatory scrutiny and consolidation first.